The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
ApexOnco Front Page
Recent articles
BeOne's degrader BG-60366 appears to have been discontinued.
Replimune gets a second chance, while Sarclisa could go subcutaneous.
After a delay, the Alpha-3 study faces an April futility analysis.
Early data are coming with the KRAS G12D degrader ARV-806.
A first-in-human trial of PRT12396 starts next month.
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
